Platelet Rich Plasma (PRP) Market Size, Share, Trends, & Industry Analysis Report By Type (Pure, Leukocyte, Pure Platelet-Rich Fibrin), By Application, By End Use, By Region – Market Forecast, 2025–2034
- Published Date:Jun-2025
- Pages: 113
- Format: PDF
- Report ID: PM5030
- Base Year: 2024
- Historical Data: 2020-2023
Market Overview
The global platelet rich plasma (PRP) market size reached USD 932.66 million in 2024, registering a CAGR of 11.7% during 2025–2034.
The increasing aging population, rising cases of orthopedic and sports-related injuries, and the wider acceptance of PRP as an effective treatment option propel its use. Additionally, advancements in medical technology and growing interest in regenerative medicine are driving the demand for PRP therapies.
PRP is a type of plasma that contains a higher concentration of platelets than normal blood. These platelets play a key role in healing by helping with blood clotting and releasing growth factors that support tissue repair. To create PRP, a small amount of the patient’s blood is taken and spun in a centrifuge to separate its components, allowing the platelet-rich portion to be collected. PRP is widely used in orthopedic treatment, sports medicine, skin treatments, and cosmetic surgery to enhance recovery and promote faster healing.
 Market.png)
The PRP market is experiencing steady growth, driven by the increasing demand for minimally invasive surgery and natural healing approaches. Many individuals are choosing PRP to treat tendon injuries, osteoarthritis, and hair loss, and for skin rejuvenation. It is especially popular among athletes and older adults seeking rapid recovery and alternatives to surgery. As the awareness of PRP therapies increases and new applications are discovered, healthcare providers and clinics are offering more PRP treatments.
Market Dynamics
Rise in Demand of PRP in Cosmetic Surgeries and Dermatology
Platelet-rich plasma (PRP) has gained remarkable popularity within the cosmetic surgery and dermatology industry for its potential to enhance skin rejuvenation and expedite the healing process. PRP is administered topically or through injections into the skin, with the aim of stimulating collagen production, refining skin texture, minimizing fine lines and wrinkles, and achieving an overall revitalized facial appearance. Moreover, the plasma is strategically injected into the scalp to encourage hair growth, enhance hair thickness, and combat hair thinning in individuals grappling with conditions such as androgenetic alopecia (common male and female pattern baldness).
Platelet rich plasma can also be synergistically combined with other treatments such as micro-needling or laser therapy to firm up loose or sagging skin on both the face and body. Its application extends to reducing the visibility of scars, including those resulting from acne or surgical procedures, by stimulating collagen production and enhancing skin texture. PRP treatments further offer the potential to enhance the appearance of the neck and chest area by reducing wrinkles and refining skin texture. Additionally, PRP can be used in conjunction with nonsurgical procedures such as dermal fillers or PDO threads to achieve a nonsurgical facelift effect. The evolving and expanding role of PRP in plastic surgeries is anticipated to provide a significant boost to the global PRP market in the future.
Growing Role of Platelet Rich Plasma (PRP) Therapy in Orthopedic and Sports Injury Treatment
Platelet rich plasma injections have gained widespread recognition as a treatment option for tendon, muscle, and ligament injuries. This therapy expedites the healing process by injecting concentrated platelets directly into the injured area, kickstarting the body's natural healing response and leading to rapid recovery times for orthopedic injuries. A notable advantage of PRP therapy is its ability to alleviate pain and reduce inflammation associated with orthopedic conditions such as tendonitis and arthritis. The future of PRP therapy holds promise with technological advancements paving the way for more precise injection delivery methods. This progress raises hopes among healthcare professionals of achieving greater accuracy in targeting specific areas, thereby enhancing therapeutic benefits for patients.
The rising prevalence of arthritis, particularly osteoarthritis, has spurred the demand for PRP. According to the Centers for Disease Control and Prevention (CDC) in the US, one in every four adults suffers from arthritis, about 53 million US adults have arthritis, and an estimated 78 million adults are expected to be affected by the disease by 2040. According to the World Health Organization, osteoarthritis was projected to become the fourth-largest cause of immobility among the Indian population, placing a significant burden on orthopedic surgeons due to the country's massive population. Moreover, an article published in the Lancet Journal in 2020 highlighted that arthritis is the leading cause of disability among adults, with knee osteoarthritis being particularly prevalent. Approximately 654 million people worldwide aged 40 and above had knee osteoarthritis, with a prevalence rate of 203 per 10,000 person-years among individuals aged 20 and above.
PRP therapy represents a transformative approach to orthopedic injury treatment, offering substantial benefits that have the potential to revolutionize the sports rehabilitation industry and elevate patient outcomes. The increasing incidence of orthopedic conditions worldwide has driven the demand for PRP therapies.
 Market Info.png)
Segmental Insights
By Type Analysis
The pure platelet-rich plasma (P-PRP) or leukocyte-poor platelet-rich plasma segment accounted for 30.3% market share in 2024 due to its distinct advantage with minimal risk and adverse effects, reducing concerns related to allergies and immune responses during treatments. P-PRP is a specialized form of PRP that is devoid of leukocytes (white blood cells) and possesses a low-density fibrin network when activated. P-PRP has gained attention in recent years due to its unique properties, making it suitable for both liquid applications and as an activated gel. This innovation has sparked significant interest among manufacturers who have invested heavily in research and development to support the health benefits associated with P-PRP.
Several factors are influencing the growth of L-PRP and the broader PRP segments in the context of orthopedics. The increasing demand for orthopedic treatments is driving the adoption of PRP therapies such as L-PRP. The growing senior population leads to the increased prevalence of musculoskeletal disorders such as osteoarthritis and osteoporosis, making regenerative treatments such as L-PRP attractive options for managing these conditions. Additionally, technological innovations in orthopedic implants and procedures have complemented PRP therapies, offering patients more comprehensive solutions for their musculoskeletal issues. These factors collectively contribute to the expansion of the PRP usage in orthopedics, where L-PRP plays a crucial role in enhancing patient outcomes and promoting faster recovery.
By Application Analysis
The dermatology segment accounted for the largest share at 22.3% in 2024, driven by the growing demand for nonsurgical cosmetic procedures such as skin rejuvenation, acne scar treatment, and hair restoration. Increased awareness of aesthetic treatments and the rising popularity of PRP for improving skin texture and hair growth significantly contributed to this growth. Dermatologists are using PRP to address diverse skin conditions, expanding treatment options. PRP's financial benefits, including practice monetization and capital access, boost industry growth by enabling investments in advanced equipment. Furthermore, PRP aids in creating solid retirement plans, ensuring financial security for dermatologists. Partnering with management groups preserves autonomy, allowing practitioners to prioritize patient care while exploring PRP's potential.
The general surgery segment is experiencing significant growth of CAGR 15.9% during 2025–2034, due to the increasing adoption of PRP to enhance wound healing and reduce post-surgical complications. Surgeons are using PRP in procedures such as breast reconstruction, spinal surgery, and cardiac surgery to promote faster tissue repair and improve patient recovery outcomes. Furthermore, both patients and healthcare professionals are becoming more aware of the advantages of using PRP in surgical settings, which is driving its adoption. This synergy between general surgery and PRP therapy is expected to continue to evolve, which will benefit patients and further fuel the growth of the general surgery segment.
By End Use Analysis
The hospitals segment dominated the market, valued at USD 682.20 million in 2024. The rise of infectious diseases has created a growing demand for safe and effective treatment options. At the same time, the number of osteoarthritis cases is also on the rise, contributing to the wider use of PRP-based therapies. Orthopedic hospitals are increasingly using PRP to relieve pain and support tissue healing in patients having osteoarthritic joints.
The growing demand for nonsurgical approaches in healthcare has positioned PRP as a valuable option, aligning with the hospital's role in offering minimally invasive treatment alternatives. Lastly, the escalating incidence of hair loss has opened up new avenues for PRP usage within hospitals, with dermatologists utilizing PRP to stimulate hair growth and improve the hair quality.
 Market Seg.png)
Regional Analysis
The North America platelet rich plasma market size reached USD 365.19 million in 2024 and is estimated to register a CAGR of 11.8% during the forecast period. This dominance is primarily driven by increasing demand for cosmetic surgeries, a high prevalence of orthopedic procedures, and a rising incidence of sports-related injuries. According to the Arthritis Foundation, as of 2024, North America witnessed 60 million adults and approximately 300,000 children diagnosed with arthritis. This statistic has propelled the demand for PRP treatments in the region.
US Platelet Rich Plasma Market Insight
The US platelet rich plasma market dominated the North America market, capturing 72.8% regional share, driven by the increasing prevalence of various disorders such as arthritis, a well-established healthcare infrastructure, a robust regulatory framework, and government support. Furthermore, micro-needling is gaining popularity in the US for various applications, including transcutaneous drug administration, in addition to its original intended use for skin rejuvenation. Hair loss affects approximately 30 million women and 50 million men in the US, with over 50% of males over the age of 50 experiencing some degree of hair loss. PRP is a commonly used technique in cosmetic procedures and other treatments, contributing to the growth of the platelet-rich plasma industry in the country.
Europe Platelet Rich Plasma Market Trend
The platelet rich plasma market in Europe is projected to reach USD 708.81 million by 2034, owing to the widespread adoption of PRP therapy for the treatment of musculoskeletal injuries. Conditions such as Achilles tendinopathy, plantar fasciitis, and tennis elbow are particularly contributing to this upward trend. Additionally, PRP therapy is gaining traction in the management of injuries among the geriatric population and sports-related injuries for a rapid healing process. The various PRP product sales from the companies present in the region indicate a significant role in influencing and stimulating the overall dynamics and growth of the PRP market. For example, Europe-based Stryker Corporation and Johnson & Johnson Inc. have established themselves as key players in this industry. Stryker Corporation's RegenKit THT A-PRP (Autologous Platelet-rich Plasma) and Johnson & Johnson's PEAK PRP System are expected to maintain strong sales performance during forecast period.
Asia Pacific Platelet Rich Plasma Market Overview
Asia Pacific accounted for a 20.5% share of the global market in 2024. The increasing prevalence of orthopedic, neurological, and cardiovascular diseases in the region, alongside a rising incidence of sports injuries, has created a critical demand for PRP therapies. Additionally, the growing issue of obesity in Asia has further fueled the need for innovative treatments such as PRP. Moreover, the development of improved equipment for PRP preparation has enhanced efficiency in the process, thus driving PRP demand. PRP treatment is considered safe and cost-efficient, as it involves the injection of platelets around injured sites to expedite healing, making it an attractive option for patients.
The rising number of individuals suffering from orthopedic ailments is also expected to boost the demand for PRP treatments. Increased awareness about PRP therapies and advancements in emerging nations such as India and China is also set to have a significant positive impact on the market.
 Market Reg.png)
Key Players and Competitive Analysis
A few key players in the industry include Vivostat; Arthrex Inc.; RegenOrthoSport; Dr. PRP USA LLC; Juventix Regenerative Medical, LLC; Terumo Cardiovascular Systems Corporation; Zimmer Biomet; Isto Biologics; Apex Biologix; and Regen Lab SA. The market is highly competitive due to the presence of these established companies, each striving to expand their share. These players are focusing on strategic initiatives such as product launches, mergers and acquisitions, technological innovations, and partnerships to strengthen their product offerings and improve clinical outcomes. The development of advanced PRP systems with improved efficiency and precision in delivery is also a key focus to meet the growing demand across orthopedic, dermatology, and general surgery applications.
Key Players
- Apex Biologix
- Arthrex Inc.
- Dr. PRP USA LLC
- Isto Biologics
- Juventix Regenerative Medical, LLC
- Regen Lab SA
- RegenOrthoSport
- Terumo Cardiovascular Systems Corporation
- Vivostat
- Zimmer Biomet
Industry Developments
February 2023: Royal Biologics launched BIOINCYTE PRFM, a next-generation platelet-rich plasma system designed to enhance the effectiveness of regenerative therapies. This advanced system transforms standard PRP into a platelet-rich fibrin matrix (PRFM), which offers a more stable and sustained release of growth factors.
March 2023: Arthrex, Inc. acquired Celling Biosciences, a company specializing in the development and manufacturing of PRP products. This strategic acquisition positions Arthrex to broaden its range of PRP offerings and extend its reach to a broader patient base.
January 2023: BC Children’s Hospital Foundation unveiled the introduction of stem cell research technology at BC Children’s Hospital ("BC Children’s"). In this technology, all facets of stem cell culturing have been integrated and automated into a single piece of equipment.
Platelet Rich Plasma Market Segmentation
By Type Outlook (Revenue, USD Million, 2020–2034)
- Pure Platelet-Rich Plasma (P-PRP)
- Leukocyte-and Platelet-Rich Plasma (L-PRP)
- Pure Platelet-Rich Fibrin (P-PRF) – or Leukocyte-Poor Platelet-Rich Fibrin
- Leukocyte- and Platelet-Rich Fibrin (L-PRF)
By Application Outlook (Revenue, USD Million, 2020–2034)
- Orthopedics
- Sports Medicine
- General Surgery
- Dermatology
- Ophthalmology
- Neurology
- Cardiology
- Others
By End Use Outlook (Revenue, USD Million, 2020–2034)
- Hospitals
- Clinics
- Others
By Regional Outlook (Revenue, USD Million, 2020–2034)
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Netherlands
- Russia
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- Malaysia
- Australia
- Indonesia
- Rest of Asia Pacific
- Middle East & Africa
- Saudi Arabia
- UAE
- Israel
- Rest of Middle East & Africa
- Latin America
- Brazil
- Argentina
- Rest of Latin America
Platelet Rich Plasma Market Report Scope
|
Report Attributes |
Details |
|
Market Size in 2024 |
USD 932.66 Million |
|
Market Size in 2025 |
USD 1,059.50 Million |
|
Revenue Forecast by 2034 |
USD 2,857.98 Million |
|
CAGR |
11.7% from 2025 to 2034 |
|
Base Year |
2024 |
|
Historical Data |
2020–2023 |
|
Forecast Period |
2025–2034 |
|
Quantitative Units |
Revenue in USD Million and CAGR from 2025 to 2034 |
|
Report Coverage |
Revenue Forecast, Competitive Landscape, Growth Factors, and Industry Trends |
|
Segments Covered |
|
|
Regional Scope |
|
|
Competitive Landscape |
|
|
Report Format |
|
|
Customization |
Report customization as per your requirements with respect to countries, regions, and segmentation. |
FAQ's
The global market size was valued at USD 932.66 million in 2024 and is projected to grow to USD 2,857.98 million by 2034.
The global market is expected to register a CAGR of 11.7% during the forecast period.
North America held the largest share of the global market in 2024.
A few key players in the market are Vivostat; Arthrex Inc.; RegenOrthoSport; Dr. PRP USA LLC; Juventix Regenerative Medical, LLC; Terumo Cardiovascular Systems Corporation; Zimmer Biomet; Isto Biologics; Apex Biologix; and Regen Lab SA.
The pure platelet-rich plasma (P-PRP) segment dominated the market in 2024.
The dermatology segment held the largest share of the global market in 2024.
© 2025 Polaris Market Research and Consulting. All rights reserved
